125 related articles for article (PubMed ID: 36815250)
1. Venetoclax analogs as promising anticancer therapeutics via targeting Bcl-2 protein:
Almansour NM; Allemailem KS; Abd El Aty AA; Boussoufa D; Ismail Fagiree E; Ibrahim MAA
J Biomol Struct Dyn; 2023; 41(23):14308-14324. PubMed ID: 36815250
[TBL] [Abstract][Full Text] [Related]
2.
Almansour NM; Allemailem KS; Abd El Aty AA; Ismail EIF; Ibrahim MAA
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677841
[TBL] [Abstract][Full Text] [Related]
3. Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.
Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Shawky AM; Mekhemer GAH; Alrumaihi F; Moustafa MF; Atia MAM
Cell Biochem Biophys; 2021 Jun; 79(2):189-200. PubMed ID: 33954893
[TBL] [Abstract][Full Text] [Related]
4. Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.
Ibrahim MAA; Mohamed EAR; Abdelrahman AHM; Allemailem KS; Moustafa MF; Shawky AM; Mahzari A; Hakami AR; Abdeljawaad KAA; Atia MAM
J Mol Graph Model; 2021 Jun; 105():107904. PubMed ID: 33798836
[TBL] [Abstract][Full Text] [Related]
5. Development of venetoclax performance using its new derivatives on BCL-2 protein inhibition.
Najafi V; Yoosefian M; Hassani Z
Cell Biochem Funct; 2023 Jan; 41(1):58-66. PubMed ID: 36259104
[TBL] [Abstract][Full Text] [Related]
6. Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study.
Ibrahim MAA; Abdelrahman AHM; Badr EAA; Almansour NM; Alzahrani OR; Ahmed MN; Soliman MES; Naeem MA; Shawky AM; Sidhom PA; Mekhemer GAH; Atia MAM
Mol Divers; 2022 Dec; 26(6):3255-3277. PubMed ID: 35224675
[TBL] [Abstract][Full Text] [Related]
7. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
[TBL] [Abstract][Full Text] [Related]
8. Pyronaridine as a Bromodomain-Containing Protein 4-
Ibrahim MAA; Abdelhamid MMH; Abdeljawaad KAA; Abdelrahman AHM; Mekhemer GAH; Sidhom PA; Sayed SRM; Paré PW; Hegazy MF; Shoeib T
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570684
[TBL] [Abstract][Full Text] [Related]
9. In silico drug discovery of SIRT2 inhibitors from natural source as anticancer agents.
Ibrahim MAA; Abdeljawaad KAA; Roshdy E; Mohamed DEM; Ali TFS; Gabr GA; Jaragh-Alhadad LA; Mekhemer GAH; Shawky AM; Sidhom PA; Abdelrahman AHM
Sci Rep; 2023 Feb; 13(1):2146. PubMed ID: 36750593
[TBL] [Abstract][Full Text] [Related]
10.
Almansour NM; Abdelrahman AHM; Ismail Fagiree E; Ibrahim MAA
J Biomol Struct Dyn; 2023; 41(16):7651-7664. PubMed ID: 36120948
[TBL] [Abstract][Full Text] [Related]
11. Development of novel monoamine oxidase B (MAO-B) inhibitors by combined application of docking-based alignment, 3D-QSAR, ADMET prediction, molecular dynamics simulation, and MM_GBSA binding free energy.
El Aissouq A; Chedadi O; Bouachrine M; Ouammou A; Khalil F
J Biomol Struct Dyn; 2023 Jul; 41(10):4667-4680. PubMed ID: 35510607
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy.
Krishna S; Kumar SB; Murthy TPK; Murahari M
Comput Biol Med; 2021 Jul; 134():104455. PubMed ID: 33962088
[TBL] [Abstract][Full Text] [Related]
13. Shedding Light on the Interaction of Human Anti-Apoptotic Bcl-2 Protein with Ligands through Biophysical and in Silico Studies.
Ramos J; Muthukumaran J; Freire F; Paquete-Ferreira J; Otrelo-Cardoso AR; Svergun D; Panjkovich A; Santos-Silva T
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781512
[TBL] [Abstract][Full Text] [Related]
14. Natural-like products as potential SARS-CoV-2 M
Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Hegazy MF
J Biomol Struct Dyn; 2021 Sep; 39(15):5722-5734. PubMed ID: 32643529
[TBL] [Abstract][Full Text] [Related]
15. Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study.
Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Jaragh-Alhadad LA; Oraby HF; Elkaeed EB; Mekhemer GAH; Gabr GA; Shawky AM; Sidhom PA; Soliman MES; Moustafa MF; Paré PW; Hegazy MF
Molecules; 2022 May; 27(10):. PubMed ID: 35630581
[TBL] [Abstract][Full Text] [Related]
16.
Gowtham HG; Ahmed F; Anandan S; Shivakumara CS; Bilagi A; Pradeep S; Shivamallu C; Shati AA; Alfaifi MY; Elbehairi SEI; Achar RR; Silina E; Stupin V; Murali M; Kollur SP
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838574
[TBL] [Abstract][Full Text] [Related]
17. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
[TBL] [Abstract][Full Text] [Related]
18. Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an
Ibrahim MAA; Abdeljawaad KAA; Jaragh-Alhadad LA; Oraby HF; Atia MAM; Alzahrani OR; Mekhemer GAH; Moustafa MF; Shawky AM; Sidhom PA; Abdelrahman AHM
J Biomol Struct Dyn; 2023; 41(23):13977-13992. PubMed ID: 36883864
[TBL] [Abstract][Full Text] [Related]
19. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
20. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
[Next] [New Search]
